Phio Pharmaceuticals Corp.

09/16/2021 | Press release | Distributed by Public on 09/16/2021 05:09

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4